APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drug

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

Selected research

Industry Growth & Trends

Global GLP-1 Drug Industry Growth and Trends Forecast to 2032

21 December 2025109 pages

Choose your research edition.

Industry ResearchGLP-1 Drug Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Read the full market overview

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

The global GLP-1 Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

The Asia Pacific market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Drug include Novo Nordisk, Eli Lilly, Sanofi, Teva, Jiangsu Hansoh Pharmaceutical, Huadong Medicine, Benemae Pharmaceutical, Tonghua Dongbao Pharma and Chia Tai-Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global GLP-1 Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The GLP-1 Drug market size, estimates, and forecasts are presented in terms of sales volume (Sales (k PMT)) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global GLP-1 Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to GLP-1 Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global GLP-1 Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

GLP-1 Drug Market by Company

Novo Nordisk

Eli Lilly

Sanofi

Teva

Jiangsu Hansoh Pharmaceutical

Huadong Medicine

Benemae Pharmaceutical

Tonghua Dongbao Pharma

Chia Tai-Tianqing Pharmaceutical

AstraZeneca

GLP-1 Drug Segment by Type

Short-acting

Long-acting

GLP-1 Drug Segment by Indications

T2D

CV risk

Obesity

GLP-1 Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Short-acting Table 2. Major Company of Long-acting Table 3. Global GLP-1 Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 5. Global GLP-1 Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global GLP-1 Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global GLP-1 Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global GLP-1 Drug Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 9. Global GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 10. Global GLP-1 Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global GLP-1 Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global GLP-1 Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global GLP-1 Drug Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 14. North America GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 15. North America GLP-1 Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 17. Europe GLP-1 Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 19. Asia-Pacific GLP-1 Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 21. Latin America GLP-1 Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 23. Middle East and Africa GLP-1 Drug Sales by Type (2021-2026) & (US$ Million) Table 24. GLP-1 Drug Industry Trends Table 25. GLP-1 Drug Industry Drivers Table 26. GLP-1 Drug Industry Opportunities and Challenges Table 27. GLP-1 Drug Industry Restraints Table 28. Global GLP-1 Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global GLP-1 Drug Revenue Market Share by Company (2021-2026) Table 30. Global GLP-1 Drug Sales by Company (2021-2026) & (Sales (k PMT)) Table 31. Global GLP-1 Drug Sales Share by Company (2021-2026) Table 32. Global GLP-1 Drug Market Price by Company (2021-2026) & (Net Price (USD/PMT)) Table 33. Global GLP-1 Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global GLP-1 Drug Major Company Production Sites and Headquarters Table 35. Global GLP-1 Drug Company, Product Type & Application Table 36. Global GLP-1 Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global GLP-1 Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global GLP-1 Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global GLP-1 Drug Sales by Region (2021-2026) & (Sales (k PMT)) Table 41. Global GLP-1 Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global GLP-1 Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global GLP-1 Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 45. Global GLP-1 Drug Sales by Region (2027-2032) & (Sales (k PMT)) Table 46. Global GLP-1 Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global GLP-1 Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global GLP-1 Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2027-2032) Table 50. Global GLP-1 Drug Sales by Indications (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 52. Global GLP-1 Drug Sales Market Share in Volume by Indications (2021-2026) Table 53. Global GLP-1 Drug Sales by Indications (2021-2026) & (US$ Million) Table 54. Global GLP-1 Drug Sales Market Share in Value by Indications (2021-2026) Table 55. Global GLP-1 Drug Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 56. Global GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 57. Global GLP-1 Drug Sales Market Share in Volume by Indications (2027-2032) Table 58. Global GLP-1 Drug Sales by Indications (2027-2032) & (US$ Million) Table 59. Global GLP-1 Drug Sales Market Share in Value by Indications (2027-2032) Table 60. Global GLP-1 Drug Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 61. North America GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 62. North America GLP-1 Drug Sales by Indications (2021-2026) & (US$ Million) Table 63. Europe GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 64. Europe GLP-1 Drug Sales by Indications (2021-2026) & (US$ Million) Table 65. Asia-Pacific GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 66. Asia-Pacific GLP-1 Drug Sales by Indications (2021-2026) & (US$ Million) Table 67. Latin America GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 68. Latin America GLP-1 Drug Sales by Indications (2021-2026) & (US$ Million) Table 69. Middle East and Africa GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 70. Middle East and Africa GLP-1 Drug Sales by Indications (2021-2026) & (US$ Million) Table 71. Novo Nordisk Company Information Table 72. Novo Nordisk Business Overview Table 73. Novo Nordisk GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 74. Novo Nordisk GLP-1 Drug Product Portfolio Table 75. Novo Nordisk Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 79. Eli Lilly GLP-1 Drug Product Portfolio Table 80. Eli Lilly Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 84. Sanofi GLP-1 Drug Product Portfolio Table 85. Sanofi Recent Development Table 86. Teva Company Information Table 87. Teva Business Overview Table 88. Teva GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 89. Teva GLP-1 Drug Product Portfolio Table 90. Teva Recent Development Table 91. Jiangsu Hansoh Pharmaceutical Company Information Table 92. Jiangsu Hansoh Pharmaceutical Business Overview Table 93. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 94. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio Table 95. Jiangsu Hansoh Pharmaceutical Recent Development Table 96. Huadong Medicine Company Information Table 97. Huadong Medicine Business Overview Table 98. Huadong Medicine GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 99. Huadong Medicine GLP-1 Drug Product Portfolio Table 100. Huadong Medicine Recent Development Table 101. Benemae Pharmaceutical Company Information Table 102. Benemae Pharmaceutical Business Overview Table 103. Benemae Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 104. Benemae Pharmaceutical GLP-1 Drug Product Portfolio Table 105. Benemae Pharmaceutical Recent Development Table 106. Tonghua Dongbao Pharma Company Information Table 107. Tonghua Dongbao Pharma Business Overview Table 108. Tonghua Dongbao Pharma GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 109. Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio Table 110. Tonghua Dongbao Pharma Recent Development Table 111. Chia Tai-Tianqing Pharmaceutical Company Information Table 112. Chia Tai-Tianqing Pharmaceutical Business Overview Table 113. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 114. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio Table 115. Chia Tai-Tianqing Pharmaceutical Recent Development Table 116. AstraZeneca Company Information Table 117. AstraZeneca Business Overview Table 118. AstraZeneca GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 119. AstraZeneca GLP-1 Drug Product Portfolio Table 120. AstraZeneca Recent Development Table 121. North America GLP-1 Drug Market Size Growth Rate (CAGR) by Country (Sales (k PMT)): 2021 VS 2025 VS 2032 Table 122. North America GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 123. North America GLP-1 Drug Sales Market Share by Country (2021-2026) Table 124. North America GLP-1 Drug Sales Forecast by Country (2027-2032) & (Sales (k PMT)) Table 125. North America GLP-1 Drug Sales Market Share Forecast by Country (2027-2032) Table 126. North America GLP-1 Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America GLP-1 Drug Market Size by Country (2021-2026) & (US$ Million) Table 128. North America GLP-1 Drug Market Share by Country (2021-2026) Table 129. North America GLP-1 Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America GLP-1 Drug Market Share Forecast by Country (2027-2032) Table 131. Europe GLP-1 Drug Market Size Growth Rate (CAGR) by Country (Sales (k PMT)): 2021 VS 2025 VS 2032 Table 132. Europe GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 133. Europe GLP-1 Drug Sales Market Share by Country (2021-2026) Table 134. Europe GLP-1 Drug Sales Forecast by Country (2027-2032) & (Sales (k PMT)) Table 135. Europe GLP-1 Drug Sales Market Share Forecast by Country (2027-2032) Table 136. Europe GLP-1 Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe GLP-1 Drug Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe GLP-1 Drug Market Share by Country (2021-2026) Table 139. Europe GLP-1 Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe GLP-1 Drug Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific GLP-1 Drug Market Size Growth Rate (CAGR) by Country (Sales (k PMT)): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 143. Asia-Pacific GLP-1 Drug Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific GLP-1 Drug Sales Forecast by Country (2027-2032) & (Sales (k PMT)) Table 145. Asia-Pacific GLP-1 Drug Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific GLP-1 Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific GLP-1 Drug Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific GLP-1 Drug Market Share by Country (2021-2026) Table 149. Asia-Pacific GLP-1 Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific GLP-1 Drug Market Share Forecast by Country (2027-2032) Table 151. Latin America GLP-1 Drug Market Size Growth Rate (CAGR) by Country (Sales (k PMT)): 2021 VS 2025 VS 2032 Table 152. Latin America GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 153. Latin America GLP-1 Drug Sales Market Share by Country (2021-2026) Table 154. Latin America GLP-1 Drug Sales Forecast by Country (2027-2032) & (Sales (k PMT)) Table 155. Latin America GLP-1 Drug Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America GLP-1 Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America GLP-1 Drug Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America GLP-1 Drug Market Share by Country (2021-2026) Table 159. Latin America GLP-1 Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America GLP-1 Drug Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa GLP-1 Drug Market Size Growth Rate (CAGR) by Country (Sales (k PMT)): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 163. Middle East and Africa GLP-1 Drug Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa GLP-1 Drug Sales Forecast by Country (2027-2032) & (Sales (k PMT)) Table 165. Middle East and Africa GLP-1 Drug Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa GLP-1 Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa GLP-1 Drug Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa GLP-1 Drug Market Share by Country (2021-2026) Table 169. Middle East and Africa GLP-1 Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa GLP-1 Drug Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. GLP-1 Drug Distributors List Table 174. GLP-1 Drug Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. GLP-1 Drug Image Figure 2. Global GLP-1 Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Drug Sales (2021-2032) & (Sales (k PMT)) Figure 5. Short-acting Image Figure 6. Global Short-acting Sales YoY Growth (2021-2032) & (Sales (k PMT)) Figure 7. Long-acting Image Figure 8. Global Long-acting Sales YoY Growth (2021-2032) & (Sales (k PMT)) Figure 9. Global GLP-1 Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global GLP-1 Drug Market Share by Type 2025 VS 2032 Figure 11. North America GLP-1 Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America GLP-1 Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe GLP-1 Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe GLP-1 Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific GLP-1 Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific GLP-1 Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America GLP-1 Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America GLP-1 Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa GLP-1 Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa GLP-1 Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 GLP-1 Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. T2D Image Figure 24. Global T2D Sales YoY Growth (2021-2032) & (Sales (k PMT)) Figure 25. CV risk Image Figure 26. Global CV risk Sales YoY Growth (2021-2032) & (Sales (k PMT)) Figure 27. Obesity Image Figure 28. Global Obesity Sales YoY Growth (2021-2032) & (Sales (k PMT)) Figure 29. Global GLP-1 Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global GLP-1 Drug Market Share by Application 2025 VS 2032 Figure 31. North America GLP-1 Drug Sales Market Share in Volume by Application in 2025 Figure 32. North America GLP-1 Drug Sales Market Share in Value by Application in 2025 Figure 33. Europe GLP-1 Drug Sales Market Share in Volume by Application in 2025 Figure 34. Europe GLP-1 Drug Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific GLP-1 Drug Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific GLP-1 Drug Sales Market Share in Value by Application in 2025 Figure 37. Latin America GLP-1 Drug Sales Market Share in Volume by Application in 2025 Figure 38. Latin America GLP-1 Drug Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa GLP-1 Drug Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa GLP-1 Drug Sales Market Share in Value by Application in 2025 Figure 41. North America GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Figure 42. North America GLP-1 Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America GLP-1 Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Figure 46. Europe GLP-1 Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe GLP-1 Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Figure 50. Asia-Pacific GLP-1 Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific GLP-1 Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Figure 54. Latin America GLP-1 Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America GLP-1 Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Figure 58. Middle East and Africa GLP-1 Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa GLP-1 Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. GLP-1 Drug Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. GLP-1 Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Short-acting
  • Long-acting
Applications
  • T2D
  • CV risk
  • Obesity
Companies covered
  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • Teva
  • Jiangsu Hansoh Pharmaceutical
  • Huadong Medicine
  • Benemae Pharmaceutical
  • Tonghua Dongbao Pharma
  • Chia Tai-Tianqing Pharmaceutical
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GLP-1 Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global GLP-1 Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 GLP-1 Drug Market by Type
  6. 1.3.1 Short-acting
  7. 1.3.2 Long-acting
  8. 1.4 Global GLP-1 Drug Market Size by Type
  9. 1.4.1 Global GLP-1 Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global GLP-1 Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global GLP-1 Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America GLP-1 Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe GLP-1 Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific GLP-1 Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America GLP-1 Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa GLP-1 Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 GLP-1 Drug Industry Trends
  2. 2.2 GLP-1 Drug Industry Drivers
  3. 2.3 GLP-1 Drug Industry Opportunities and Challenges
  4. 2.4 GLP-1 Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by GLP-1 Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by GLP-1 Drug Sales (2021-2026)
  3. 3.3 Global Top Players by GLP-1 Drug Price (2021-2026)
  4. 3.4 Global GLP-1 Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GLP-1 Drug Major Company Production Sites & Headquarters
  6. 3.6 Global GLP-1 Drug Company, Product Type & Application
  7. 3.7 Global GLP-1 Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GLP-1 Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GLP-1 Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GLP-1 Drug Tier 1, Tier 2, and Tier 3
4 GLP-1 Drug Regional Status and Outlook
  1. 4.1 Global GLP-1 Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global GLP-1 Drug Historic Market Size by Region
  3. 4.2.1 Global GLP-1 Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global GLP-1 Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global GLP-1 Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global GLP-1 Drug Forecasted Market Size by Region
  7. 4.3.1 Global GLP-1 Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global GLP-1 Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global GLP-1 Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 GLP-1 Drug by Application
  1. 5.1 GLP-1 Drug Market by Indications
  2. 5.1.1 T2D
  3. 5.1.2 CV risk
  4. 5.1.3 Obesity
  5. 5.2 Global GLP-1 Drug Market Size by Indications
  6. 5.2.1 Global GLP-1 Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global GLP-1 Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global GLP-1 Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Indications
  10. 5.3.1 North America GLP-1 Drug Sales Breakdown by Indications (2021-2026)
  11. 5.3.2 Europe GLP-1 Drug Sales Breakdown by Indications (2021-2026)
  12. 5.3.3 Asia-Pacific GLP-1 Drug Sales Breakdown by Indications (2021-2026)
  13. 5.3.4 South America GLP-1 Drug Sales Breakdown by Indications (2021-2026)
  14. 5.3.5 Middle East and Africa GLP-1 Drug Sales Breakdown by Indications (2021-2026)
6 Company Profiles
  1. 6.1 Novo Nordisk
  2. 6.1.1 Novo Nordisk Company Information
  3. 6.1.2 Novo Nordisk Business Overview
  4. 6.1.3 Novo Nordisk GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novo Nordisk GLP-1 Drug Product Portfolio
  6. 6.1.5 Novo Nordisk Recent Developments
  7. 6.2 Eli Lilly
  8. 6.2.1 Eli Lilly Company Information
  9. 6.2.2 Eli Lilly Business Overview
  10. 6.2.3 Eli Lilly GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Eli Lilly GLP-1 Drug Product Portfolio
  12. 6.2.5 Eli Lilly Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi GLP-1 Drug Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Teva
  20. 6.4.1 Teva Company Information
  21. 6.4.2 Teva Business Overview
  22. 6.4.3 Teva GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Teva GLP-1 Drug Product Portfolio
  24. 6.4.5 Teva Recent Developments
  25. 6.5 Jiangsu Hansoh Pharmaceutical
  26. 6.5.1 Jiangsu Hansoh Pharmaceutical Company Information
  27. 6.5.2 Jiangsu Hansoh Pharmaceutical Business Overview
  28. 6.5.3 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio
  30. 6.5.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  31. 6.6 Huadong Medicine
  32. 6.6.1 Huadong Medicine Company Information
  33. 6.6.2 Huadong Medicine Business Overview
  34. 6.6.3 Huadong Medicine GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Huadong Medicine GLP-1 Drug Product Portfolio
  36. 6.6.5 Huadong Medicine Recent Developments
  37. 6.7 Benemae Pharmaceutical
  38. 6.7.1 Benemae Pharmaceutical Company Information
  39. 6.7.2 Benemae Pharmaceutical Business Overview
  40. 6.7.3 Benemae Pharmaceutical GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Benemae Pharmaceutical GLP-1 Drug Product Portfolio
  42. 6.7.5 Benemae Pharmaceutical Recent Developments
  43. 6.8 Tonghua Dongbao Pharma
  44. 6.8.1 Tonghua Dongbao Pharma Company Information
  45. 6.8.2 Tonghua Dongbao Pharma Business Overview
  46. 6.8.3 Tonghua Dongbao Pharma GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio
  48. 6.8.5 Tonghua Dongbao Pharma Recent Developments
  49. 6.9 Chia Tai-Tianqing Pharmaceutical
  50. 6.9.1 Chia Tai-Tianqing Pharmaceutical Company Information
  51. 6.9.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  52. 6.9.3 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio
  54. 6.9.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  55. 6.10 AstraZeneca
  56. 6.10.1 AstraZeneca Company Information
  57. 6.10.2 AstraZeneca Business Overview
  58. 6.10.3 AstraZeneca GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AstraZeneca GLP-1 Drug Product Portfolio
  60. 6.10.5 AstraZeneca Recent Developments
7 North America by Country
  1. 7.1 North America GLP-1 Drug Sales by Country
  2. 7.1.1 North America GLP-1 Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America GLP-1 Drug Sales by Country (2021-2026)
  4. 7.1.3 North America GLP-1 Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America GLP-1 Drug Market Size by Country
  6. 7.2.1 North America GLP-1 Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America GLP-1 Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America GLP-1 Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe GLP-1 Drug Sales by Country
  2. 8.1.1 Europe GLP-1 Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe GLP-1 Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe GLP-1 Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe GLP-1 Drug Market Size by Country
  6. 8.2.1 Europe GLP-1 Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe GLP-1 Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe GLP-1 Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific GLP-1 Drug Sales by Country
  2. 9.1.1 Asia-Pacific GLP-1 Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific GLP-1 Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific GLP-1 Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific GLP-1 Drug Market Size by Country
  6. 9.2.1 Asia-Pacific GLP-1 Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific GLP-1 Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific GLP-1 Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America GLP-1 Drug Sales by Country
  2. 10.1.1 South America GLP-1 Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America GLP-1 Drug Sales by Country (2021-2026)
  4. 10.1.3 South America GLP-1 Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America GLP-1 Drug Market Size by Country
  6. 10.2.1 South America GLP-1 Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America GLP-1 Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America GLP-1 Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa GLP-1 Drug Sales by Country
  2. 11.1.1 Middle East and Africa GLP-1 Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa GLP-1 Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa GLP-1 Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa GLP-1 Drug Market Size by Country
  6. 11.2.1 Middle East and Africa GLP-1 Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa GLP-1 Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa GLP-1 Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 GLP-1 Drug Value Chain Analysis
  2. 12.1.1 GLP-1 Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 GLP-1 Drug Production Mode & Process
  7. 12.2 GLP-1 Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 GLP-1 Drug Distributors
  10. 12.2.3 GLP-1 Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst